We are monitoring the impact of COVID-19 on North America Autoimmune Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1106
Share on
Share on

North America Autoimmune Monoclonal Antibodies Market Research Report – Segmented By Source, Application, End User & Country (United States, Canada & Rest of North America) – Industry Size, Share, Trends, Growth & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 1106
Pages: 145

North America Autoimmune Monoclonal Antibodies Market Size & Growth (2021 to 2026)

The size of the North America Autoimmune Monoclonal Antibodies Market is expected to reach USD 14771.27 million by 2026 from USD 9837.16 million in 2021, growing at a CAGR of 8.47% during the forecast period 2021 to 2026. 

Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This leads to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and other diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs have made switched to concentrate on monoclonal antibodies.

Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat a wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.

A growing number of patients with autoimmune diseases, increasing research and development to promote the development of monoclonal antibodies, the presence of a large number of biotechnology companies, and rising demand for effective therapeutics are driving the growth of autoimmune monoclonal antibodies market in North America. In addition, increasing innovations in monoclonal antibodies research, rising number of product launches, and a growing number of collaborations & agreements to promote autoimmune therapies using monoclonal antibodies are further supporting the growth of autoimmune monoclonal antibodies market in North America.

However, stringent regulatory pathways and lack of proper reimbursement policies are expected to limit the growth of the autoimmune monoclonal antibodies market in North America.

This research report on the North America Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Application:

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Transplant Rejection/Graft Versus Host Disease

By End-User: 

  • Hospitals/Clinics
  • Research Institutes
  • Diagnostic Laboratories

By Country:

  • United States
  • Canada
  • Rest of North America

On the basis of source, the humanized segment is expected to command the largest share in North America Autoimmune Monoclonal Antibodies market, by the source in 2019.

On the basis of application, the rheumatoid arthritis application is anticipated to command the major share in North America Autoimmune Monoclonal Antibodies market, by application in 2019.

On the basis of end-user, the Hospitals/Clinics segment is expected to hold the major market share in North America Autoimmune Monoclonal Antibodies market, by application in 2016.

The key players dominating the North American Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.3 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.6 Innovent Biologics, Inc. (China)                          

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Autoimmune Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  2. North America Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  3. North America Murine Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  4. North America Chimeric Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  5. North America Humanized Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  6. North America Human Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  7. North America Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  8. North America Systemic Lupus Erythematosus Market By Region, From 2021 to 2026 (USD Million)
  9. North America Rheumatoid Arthritis Market By Region, From 2021 to 2026 (USD Million)
  10. North America Multiple Sclerosis Market By Region, From 2021 to 2026 (USD Million)
  11. North America Transplant Rejection/Graft Versus Host Disease Market By Region, From 2021 to 2026 (USD Million)
  12. North America Other Applications Market By Region, From 2021 to 2026 (USD Million)
  13. North America Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  14. North America Hospitals/Clinics Market By Region, From 2021 to 2026 (USD Million)
  15. North America Research Institute Market By Region, From 2021 to 2026 (USD Million)
  16. North America Diagnostic Laboratories Market By Region, From 2021 to 2026 (USD Million)
  17. United States Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  18. United States Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  19. United States Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  20. Canada Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  21. Canada Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  22. Canada Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample